Genomic Health To Present Results On Oncotype DX Prostate Cancer Test

Genomic Health To Present Results On Oncotype DX Prostate Cancer Test
Genomic Health, Inc. has announced it will present several studies during the 2014 Society of Urologic Oncology (SUO) Annual Meeting, including the second clinical validation study of the Oncotype DX prostate cancer test. Oncotype DX Prostate Cancer Assay is a genomic test performed on a patient’s needle biopsy and provides essential information regarding the biology

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *